Clinical trials: Crohn's Diseases
Crohn's Disease
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
- Trial name
- NCT02065570
- Testing
- Adalimumab
- Where
- 143 sites in United States, Austria and 18 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Ulcerative Colitis, Crohn's Disease
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
- Trial name
- FENNEL (NCT03478956)
- Testing
- Etrolizumab
- Where
- 5 sites in Belgium, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT03105128
- Testing
- risankizumab IV, risankizumab SC
- Where
- 475 sites in United States, Argentina and 42 more
- Volunteers
- 931 people
- Sponsor
- AbbVie
Crohn's Disease
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation…
- Trial name
- NCT03850509
- Testing
- OPS-2071
- Where
- 31 sites in United States, Poland
- Volunteers
- 3 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Crohn Disease
Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study
To assess the safety and efficacy of transcutaneous vagal stimulation in adult patients with active Crohn's disease.
- Trial name
- VNS (NCT05165108)
- Testing
- Vagal Nerve Stimulator
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease, Inflammatory Bowel Disease
Dietary Treatment of Crohn's Disease
Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.
- Trial name
- NCT00343642
- Testing
- Active fructo-oligosaccharide, Diet
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Rush University Medical Center
Crohn's Disease
Safety of Celecoxib in Patients With Crohn's Disease
The investigators will select 60 people who are 18-70 years of age with Crohn's disease and randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a placebo.
- Trial name
- NCT00177866
- Testing
- Celebrex
- Volunteers
- 28 people
- Sponsor
- University of Pittsburgh
Granulomatous Colitis, Crohn's Disease
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
- Conditions
- Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
- Trial name
- NCT03599622
- Testing
- BMS-986165
- Where
- 259 sites in United States, Australia and 24 more
- Volunteers
- 239 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis, Crohn's Disease
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD).
- Trial name
- NCT04738942
- Testing
- Vedolizumab
- Where
- 20 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis, Crohn's Disease
Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Iron deficiency anaemia is common in inflammatory bowel disease (IBD), affecting at least 20% patients at any one time. Hepcidin, a recently described anti-microbial peptide synthesized by the liver, is a key regulator of iron…
- Trial name
- NCT01991314
- Testing
- Ferrous sulphate
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Queen Mary University of London
Inflammatory Bowel Disease, Perianal Fistula
Perianal Fistula (PAF) Validation and Burden of Illness Study
The purpose of this study is to gain a better understanding of the disease burden and unmet need of perianal fistulas within Crohn's disease (CD) in Ontario.
- Conditions
- Inflammatory Bowel Disease, Perianal Fistula, Crohns Disease
- Trial name
- NCT03981939
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 3,032 people
- Sponsor
- Takeda
Crohn Disease, Ulcerative Colitis
Autoimmune Protocol Diet and Inflammatory Bowel Disease
There is limited data to guide the use of dietary change in the management of IBD, and it can prove challenging to implement in the setting of altered anatomy, comorbid conditions, and patient compliance.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT03512327
- Testing
- Autoimmune protocol (AIP) diet
- Volunteers
- 15 people
- Sponsor
- Scripps Health
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
Crohn Disease
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
This study is a proof of concept, multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066/ABBV-066 (risankizumab), an IL-23 p19 antagonist monoclonal antibody, in…
- Trial name
- NCT02031276
- Testing
- risankizumab IV, risankizumab SC
- Volunteers
- 121 people
- Sponsor
- AbbVie
Axial Spondyloarthritis, Crohn Disease
MRE as a Screening Tool for axSpA in IBD
This study aims to assess the effectiveness (specificity and sensitivity) of using magnetic resonance enterography (MRE) as a screening tool for axial spondyloarthritis (axSpA) in patients with Crohns disease.
- Trial name
- ProSpA-CD (NCT03817983)
- Testing
- MRE review for evidence of axSpA in SIJs, Clinical assessment and dedicated MRI of the spine and pelvis
- Where
- United Kingdom
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Crohn Disease, Ulcerative Colitis
Digital Behavioral Interventions in Inflammatory Bowel Disease
Given the bidirectionality between psychological distress and disease activity in inflammatory bowel disease (IBD), whereby increased psychological distress exacerbates disease activity and vice versa, psychosocial aspects of IBD…
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases, Stress, Psychological
- Trial name
- NCT04861597
- Testing
- Internet based cognitive behavioral therapy, Digital mood tracking
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer